1. Home
  2. MTRN vs ARQT Comparison

MTRN vs ARQT Comparison

Compare MTRN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTRN
  • ARQT
  • Stock Information
  • Founded
  • MTRN 1931
  • ARQT 2016
  • Country
  • MTRN United States
  • ARQT United States
  • Employees
  • MTRN N/A
  • ARQT N/A
  • Industry
  • MTRN Industrial Specialties
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTRN Industrials
  • ARQT Health Care
  • Exchange
  • MTRN Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • MTRN 1.8B
  • ARQT 1.7B
  • IPO Year
  • MTRN N/A
  • ARQT 2020
  • Fundamental
  • Price
  • MTRN $113.39
  • ARQT $15.99
  • Analyst Decision
  • MTRN Strong Buy
  • ARQT Strong Buy
  • Analyst Count
  • MTRN 2
  • ARQT 7
  • Target Price
  • MTRN $123.50
  • ARQT $19.00
  • AVG Volume (30 Days)
  • MTRN 240.8K
  • ARQT 1.8M
  • Earning Date
  • MTRN 07-30-2025
  • ARQT 08-06-2025
  • Dividend Yield
  • MTRN 0.51%
  • ARQT N/A
  • EPS Growth
  • MTRN N/A
  • ARQT N/A
  • EPS
  • MTRN 0.78
  • ARQT N/A
  • Revenue
  • MTRN $1,725,574,000.00
  • ARQT $263,464,999.00
  • Revenue This Year
  • MTRN $0.61
  • ARQT $61.83
  • Revenue Next Year
  • MTRN $6.78
  • ARQT $36.55
  • P/E Ratio
  • MTRN $146.36
  • ARQT N/A
  • Revenue Growth
  • MTRN 5.52
  • ARQT 99.50
  • 52 Week Low
  • MTRN $69.10
  • ARQT $8.03
  • 52 Week High
  • MTRN $123.21
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • MTRN 70.03
  • ARQT 56.88
  • Support Level
  • MTRN $108.67
  • ARQT $15.43
  • Resistance Level
  • MTRN $114.68
  • ARQT $17.29
  • Average True Range (ATR)
  • MTRN 3.29
  • ARQT 0.97
  • MACD
  • MTRN -0.47
  • ARQT 0.06
  • Stochastic Oscillator
  • MTRN 87.11
  • ARQT 63.70

About MTRN Materion Corporation

Materion Corp specializes in the development of specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings. The company operates in four reportable segments: Performance Materials, Electronic Materials, Precision Optics, and Others. The majority of revenue is derived from Electronic Materials which produces chemicals, microelectronics packaging, precious metal, non-precious metal, and specialty metal products, including vapor deposition targets, frame lid assemblies, clad and precious metal pre-forms. The Performance Materials segment provides engineered solutions comprised of beryllium and non-beryllium-containing alloy systems and custom-engineered parts.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: